# Massachusetts General Hospital: Phase 3 study in HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) (124 participants)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Sponsor type | Academic and hospital |
| Study | Reducing Arterial Inflammation Using Eplerenone and Statins in HIV |
| NCT ID | NCT07892664 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | HIV (Human Immunodeficiency Virus); Cardiovascular Diseases (CVD); Arterial Inflammation; Heart Disease |
| Intervention types | drug |
| Target enrollment | 124 |
| Site countries | United States |
| Posted | 2026-10-23 |
| Planned start | 2027-03-01 |
| Event | Newly registered study |
| Event date | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Phase 3: multi-site, larger budget.
- 124 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07892664). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.